

EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting

Paris, France, 13 September, 2023 - EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today on oral presentation of preclinical data on its lead asset EG110A, a novel non-replicative herpes simplex virus Type 1 (HSV1)-derived vector expressing the light chain of botulinum toxin F, at the International Continence Society's annual meeting (ICS 2023), being held September 27-29, 2023 in Toronto, Canada.

"These very promising preclinical results underlie the potential of EG110A to become the first gene therapy product to treat neurogenic bladder overactivity and other bladder pathologies. This is based on our unique ability to deliver gene therapies to targeted tissues with pinpoint accuracy," said Philippe Chambon, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of EG 427. "We are now finalizing preparations to move EG110A into clinical development, and are looking forward to submitting our Investigational New Drug application in Q1 2024."

Neurogenic detrusor overactivity (NDO) occurs in most spinal cord injury patients. These permanent lower urinary tract dysfunctions cause spontaneous involuntary bladder muscle contractions and are responsible for the development of high bladder pressures and uncontrolled urinary incontinence. NDO is a medical threat to the kidneys if not properly managed; it is not adequately controlled by available therapeutics and has a highly detrimental impact on quality of life of affected people.

The data presented at the ICS 2023, from a study in adult female rats, looked at the ability of EG110A to inhibit bladder sensory type-C fibers in an acute intravesical capsaicin model. Capsaicin acts on type-C sensory nerves via vanilloid receptors. This model has been described as relevant for the assessment of drug efficacy in NDO, and also overactive bladder.

The results showed that during capsaicin perfusion, EG110A apparently counteracted bladder irritation elicited by capsaicin-mediated activation of receptors in C-fiber bladder afferents, as evidenced by a significant decrease in the frequency of micturition and increase in the bladder capacity. The study demonstrated that EG110A, due to its selective effect on C-fibers, reduced the frequency of micturition under capsaicin irritation without any change in normal bladder function and, importantly, had no impact on voiding capability, which is the main drawback of most currently approved drugs. Furthermore, administration of EG110A was shown to be safe over the 5-week period of the experiment.

Details of the oral presentation:

Title: Intravesical administration of EG110A, a novel non-replicative herpes simplex virus Type 1 (HSV1)-derived vector expressing the light chain of botulinum toxin F, inhibits C-type fibers in an acute intravesical capsaicin rat model


Session S13: Pelvic pain and inflammation

Time: September 28, 2023 - 9am (local time)

Location: Toronto, Canada

Presenting: Julien Ratelade, preclinical project manager at EG 427

For the full abstract, please click [here](#).



EG 427 (Paris,France) has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond. Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.

For more information:

🌐 check our website at www.eg427.com
follows us on [LinkedIn](#) at [EG427](#)

Contacts:

EG 427

Philippe Chambon, M.D., Ph.D.
Founder and CEO
philippe@eg427.com

Investors

Chris Maggos
Cohesion Bureau
chris.maggos@cohesionbureau.com
+41 79 367 62 54

Media

United States

Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusein@burnsmc.com
[mailto:/ rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

Europe

Sophie Baumont
Cohesion Bureau
sophie.baumont@cohesionbureau.com
+33 6 27 74 74 49

